C F Deacon

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. pmc Valine pyrrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced beta-cell mass
    Marianne Olholm Larsen
    Department of Pharmacological Research I, Novo Nordisk A S, Bagsvaerd, Denmark
    Exp Diabesity Res 4:93-105. 2003
  2. ncbi request reprint Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes
    Michael A Nauck
    Medizinische Klinik 1, St Josef Hospital, Ruhr Universitat Bochum, Bochum D 44791, Germany
    Regul Pept 122:209-17. 2004
  3. ncbi request reprint Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight
    Jakob Hagen Schou
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    J Clin Endocrinol Metab 90:4912-9. 2005
  4. ncbi request reprint Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
    Gary A Herman
    Merck Research Laboratories, Experimental Medicine, Rahway, New Jersey 07065, USA
    J Clin Endocrinol Metab 91:4612-9. 2006
  5. ncbi request reprint Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats
    Lotte Simonsen
    Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Am J Physiol Gastrointest Liver Physiol 293:G288-95. 2007
  6. pmc Potential of liraglutide in the treatment of patients with type 2 diabetes
    Carolyn F Deacon
    Department of Biomedical Sciences, Panum Institute, Copenhagen N, Denmark ku dk
    Vasc Health Risk Manag 5:199-211. 2009
  7. ncbi request reprint Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes
    Carolyn F Deacon
    University of Copenhagen, Department of Biomedical Sciences, Panum Institute, DK 2200, Copenhagen N, Denmark
    Curr Opin Investig Drugs 9:402-13. 2008
  8. doi request reprint Immunoassays for the incretin hormones GIP and GLP-1
    Carolyn F Deacon
    Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Best Pract Res Clin Endocrinol Metab 23:425-32. 2009
  9. ncbi request reprint DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
    Carolyn F Deacon
    Department of Biomedical Sciences, Panum Institute, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Front Biosci 13:1780-94. 2008
  10. ncbi request reprint Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
    Carolyn F Deacon
    Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Diabetes Obes Metab 9:23-31. 2007

Collaborators

Detail Information

Publications71

  1. pmc Valine pyrrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced beta-cell mass
    Marianne Olholm Larsen
    Department of Pharmacological Research I, Novo Nordisk A S, Bagsvaerd, Denmark
    Exp Diabesity Res 4:93-105. 2003
    ..The authors conclude that DPPIV inhibitors may be useful to treat type 2 diabetes, even when this is due to reduced beta-cell mass...
  2. ncbi request reprint Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes
    Michael A Nauck
    Medizinische Klinik 1, St Josef Hospital, Ruhr Universitat Bochum, Bochum D 44791, Germany
    Regul Pept 122:209-17. 2004
    ....
  3. ncbi request reprint Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight
    Jakob Hagen Schou
    Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
    J Clin Endocrinol Metab 90:4912-9. 2005
    ..Low birth weight (LBW) is associated with increased risk of type 2 diabetes mellitus. An impaired incretin effect was reported previously in type 2 diabetic patients...
  4. ncbi request reprint Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
    Gary A Herman
    Merck Research Laboratories, Experimental Medicine, Rahway, New Jersey 07065, USA
    J Clin Endocrinol Metab 91:4612-9. 2006
    ..The degree of DPP-4 inhibition and the level of active incretin augmentation required for glucose lowering efficacy after an oral glucose tolerance test (OGTT) were evaluated...
  5. ncbi request reprint Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats
    Lotte Simonsen
    Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Am J Physiol Gastrointest Liver Physiol 293:G288-95. 2007
    ..In conclusion, the continued presence of Ex-4 is necessary to maintain weight loss in GK rats. Effective antihyperglycemic treatment with Ex-4 increases intestinal mass reversibly, whereas DPPIV-I lacks intestinal effects...
  6. pmc Potential of liraglutide in the treatment of patients with type 2 diabetes
    Carolyn F Deacon
    Department of Biomedical Sciences, Panum Institute, Copenhagen N, Denmark ku dk
    Vasc Health Risk Manag 5:199-211. 2009
    ..These tend to be most pronounced during the initial period of therapy and decline with time. Further clinical experience with liraglutide will reveal its long-term durability, safety and efficacy...
  7. ncbi request reprint Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes
    Carolyn F Deacon
    University of Copenhagen, Department of Biomedical Sciences, Panum Institute, DK 2200, Copenhagen N, Denmark
    Curr Opin Investig Drugs 9:402-13. 2008
    ..In January 2008, Takeda announced that an NDA for alogliptin had been submitted to the FDA...
  8. doi request reprint Immunoassays for the incretin hormones GIP and GLP-1
    Carolyn F Deacon
    Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Best Pract Res Clin Endocrinol Metab 23:425-32. 2009
    ..The use of highly specific assays using well-characterised antisera and careful sample handling is therefore required for a reliable determination of incretin hormone concentrations...
  9. ncbi request reprint DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
    Carolyn F Deacon
    Department of Biomedical Sciences, Panum Institute, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Front Biosci 13:1780-94. 2008
    ..This article focuses on DPP-4 inhibitors...
  10. ncbi request reprint Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
    Carolyn F Deacon
    Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Diabetes Obes Metab 9:23-31. 2007
    ..g. sitagliptin and vildagliptin). Clinical trials of these incretin-based therapies have shown them to be effective in improving glycaemic control in patients with T2DM...
  11. ncbi request reprint Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?
    Carolyn F Deacon
    Department of Medical Physiology, Panum Institute, University of Copenhagen, DK 2200 Copenhagen N, Denmark
    Expert Opin Investig Drugs 13:1091-102. 2004
    ..DPP IV inhibitors combine several features of interest to the drug design process. They can be readily optimised for their target and be designed as low molecular weight, orally active entities compatible with once-daily administration...
  12. ncbi request reprint Therapeutic strategies based on glucagon-like peptide 1
    Carolyn F Deacon
    Department of Medical Physiology, Panum Institute, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Diabetes 53:2181-9. 2004
    ..Such strategies include DPP-IV-resistant GLP-1 analogs and selective enzyme inhibitors to prevent in vivo degradation of the peptide...
  13. ncbi request reprint Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes
    Carolyn F Deacon
    Panum Institute, Department of Biomedical Sciences, University of Copenhagen, Copenhagen N, Denmark
    Expert Opin Investig Drugs 16:533-45. 2007
    ..Further clinical experience with sitagliptin will reveal its long-term durability, safety and efficacy...
  14. ncbi request reprint Circulation and degradation of GIP and GLP-1
    C F Deacon
    Department of Medical Physiology, The Panum Institute, 2200 Copenhagen N, Denmark
    Horm Metab Res 36:761-5. 2004
    ....
  15. ncbi request reprint GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations
    Carolyn F Deacon
    Dept of Medical Physiology, The Panum Institute, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Am J Physiol Endocrinol Metab 291:E468-75. 2006
    ..We conclude that, although GIP-(3-42) can weakly antagonize cAMP accumulation and insulin output in vitro, it does not behave as a physiological antagonist in vivo...
  16. ncbi request reprint What do we know about the secretion and degradation of incretin hormones?
    Carolyn F Deacon
    Department of Medical Physiology, The Panum Institute, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Regul Pept 128:117-24. 2005
    ..The intact peptides are inactivated during passage across the hepatic bed and further metabolised by the peripheral tissues, while the kidney is important for the final elimination of the metabolites...
  17. ncbi request reprint MK-431 (Merck)
    Carolyn F Deacon
    Department of Medical Physiology, Panum Institute, University of Copenhagen, DK 2200 Copenhagen N, Denmark
    Curr Opin Investig Drugs 6:419-26. 2005
    ..Phase III studies were initiated in the second quarter of 2004...
  18. ncbi request reprint Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes
    Carolyn F Deacon
    Department of Medical Physiology, Panum Institute, University of Copenhagen, Denmark
    Int J Biochem Cell Biol 38:831-44. 2006
    ..These have different properties, in terms of their duration of action and anticipated dosing frequency, but data from protracted dosing studies is presently not available to allow comparison of their clinical efficacy...
  19. ncbi request reprint Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig
    C F Deacon
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Denmark
    Diabetes 47:764-9. 1998
    ..9 40 min x pmol x l(-1); P < 0.05). These results suggest that by reducing GLP-1 degradation, DPP IV inhibition potentiates the insulinotropic effect of GLP-1 and may, therefore, be a viable approach to the management of diabetes...
  20. doi request reprint Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Carolyn F Deacon
    Department of Biomedical Sciences, Panum Institute, DK 2200 Copenhagen N, Denmark
    Adv Ther 26:488-99. 2009
    ..Saxagliptin is being co-developed by Bristol-Myers-Squibb (New York, NY, USA) and AstraZeneca (Cheshire, UK), and is currently undergoing regulatory review...
  21. ncbi request reprint Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs
    C F Deacon
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Diabetes 50:1588-97. 2001
    ..Nevertheless, DPP IV inhibition increases the proportion of intact peptide sufficiently to enhance its insulinotropic and antihyperglycemic effects...
  22. ncbi request reprint GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion
    Carolyn F Deacon
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, DK 2200 Copenhagen, Denmark
    Am J Physiol Endocrinol Metab 282:E873-9. 2002
    ..Moreover, the metabolite itself possesses anti-hyperglycemic effects, supporting the hypothesis that selective DPP IV action is important in glucose homeostasis...
  23. ncbi request reprint Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective
    Carolyn F Deacon
    Department of Medical Physiology, The Panum Institute, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Biochem Biophys Res Commun 294:1-4. 2002
  24. ncbi request reprint Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
    C F Deacon
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Denmark
    J Clin Endocrinol Metab 85:3575-81. 2000
    ..05). We conclude that dipeptidyl peptidase IV is important in GIP metabolism in humans in vivo, and that an N-terminally directed assay is required for determination of plasma concentrations of biologically active GIP...
  25. doi request reprint Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
    Carolyn F Deacon
    University of Copenhagen, Panum Institute, Department of Biomedical Sciences, DK 2200 Copenhagen N, Denmark
    Expert Opin Investig Drugs 19:133-40. 2010
    ..Type 2 diabetes is a progressive disease for which current treatments are often unsatisfactory with respect to achieving therapeutic goals and unwanted side effects...
  26. ncbi request reprint Differential regional metabolism of glucagon in anesthetized pigs
    Carolyn F Deacon
    Department of Medical Physiology, The Panum Institute, Blegdamsvej 3, DK 2200 Copenhagen, Denmark
    Am J Physiol Endocrinol Metab 285:E552-60. 2003
    ....
  27. ncbi request reprint Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs
    C F Deacon
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    J Endocrinol 172:355-62. 2002
    ..Total incretin secretion was reduced by DPP IV inhibition, suggesting the possibility of a feedback mechanism...
  28. doi request reprint Long-term exendin-4 treatment delays natural deterioration of glycaemic control in diabetic Goto-Kakizaki rats
    L Simonsen
    Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
    Diabetes Obes Metab 11:884-90. 2009
    ..The present study aimed to evaluate whether long-term administration of exendin-4 to GK rats in the diabetic period would improve their diabetes and how glycaemic control was affected following drug wash-out...
  29. ncbi request reprint Glucose-stimulated prehepatic insulin secretion is associated with circulating alanine, triglyceride, glucagon, lactate and TNF-alpha in patients with HIV-lipodystrophy
    S B Haugaard
    Department of Infectious Diseases, Hvidovre University Hospital, Hvidovre, Copenhagen, Denmark
    HIV Med 7:163-72. 2006
    ....
  30. doi request reprint Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus
    K Aaboe
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Diabetes Obes Metab 12:323-33. 2010
    ....
  31. ncbi request reprint Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors
    J J Holst
    Department of Medical Physiology, University of Copenhagen, The Panum Institute, Blegdamsvej 3, 2200 Copenhagen N, Denmark
    Diabetologia 48:612-5. 2005
  32. ncbi request reprint The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
    Bogdan Balas
    Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Drive, MC 7886, San Antonio, Texas 78229, USA
    J Clin Endocrinol Metab 92:1249-55. 2007
    ..However, little is known about the mechanism(s) by which vildagliptin promotes reduction in plasma glucose concentration...
  33. ncbi request reprint Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT
    Yan ling He
    DMSc, Exploratory Development, Novartis Institutes of Biomedical Research Inc, 400 Technology Square, Building 605, Rm 811, Cambridge, MA 02139 3584, USA
    J Clin Pharmacol 47:633-41. 2007
    ..Unlike findings during mixed-meal challenges, vildagliptin increases plasma insulin levels during oral glucose tolerance tests in patients with type 2 diabetes mellitus...
  34. ncbi request reprint Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Diabetes 50:609-13. 2001
    ....
  35. doi request reprint The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs
    L Simonsen
    University of Copenhagen, Department of Biomedical Sciences, Panum Institute, Blegdamsvej 3, 2200 Copenhagen N, Denmark
    Regul Pept 181:17-21. 2013
    ..In conclusion, the COOH-terminal extension of Ex-4 contributes minimally to the increased survival time of Ex-4, while addition of this sequence to GLP-1 significantly reduces its clearance...
  36. ncbi request reprint Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
    J J Holst
    Department of Medical Physiology, University of Copenhagen, Denmark
    Diabetes 47:1663-70. 1998
    ..Thus, DPP-IV inhibition may be an effective supplement to diet and exercise treatment in attempts to prevent the deterioration of glucose metabolism associated with the Western lifestyle...
  37. ncbi request reprint Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy
    O Andersen
    Department of Infectious Diseases, Hvidovre University Hospital, Copenhagen, Denmark
    HIV Med 6:91-8. 2005
    ....
  38. ncbi request reprint Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig
    A Plamboeck
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Diabetologia 48:1882-90. 2005
    ..Dipeptidyl peptidase IV (DPP-IV) is established as the primary inactivating enzyme, but the roles of other enzymes remain unclear...
  39. ncbi request reprint The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice
    Bidda Rolin
    Novo Nordisk, DK 2880 Bagsvaerd, Denmark
    Am J Physiol Endocrinol Metab 283:E745-52. 2002
    ..In conclusion, NN2211 reduced blood glucose after acute and chronic treatment in ob/ob and db/db mice and was associated with increased beta-cell mass and proliferation in db/db mice. NN2211 is currently in phase 2 clinical development...
  40. doi request reprint Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
    C F Deacon
    Department of Biomedical Sciences, Copenhagen University, Copenhagen, Denmark
    Diabetes Obes Metab 14:762-7. 2012
    ....
  41. doi request reprint Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials
    Sten Madsbad
    Department of Endocrinology, Hvidovre University Hospital, Hvidovre and University of Copenhagen, Copenhagen N, Denmark
    Curr Opin Clin Nutr Metab Care 11:491-9. 2008
    ..To discuss the virtues and shortcomings of the glucagon-like peptide-1 receptor agonists and the dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes...
  42. ncbi request reprint Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes
    Koichiro Azuma
    Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    J Clin Endocrinol Metab 93:459-64. 2008
    ..We undertook a double-blinded, randomized-order, crossover study to examine the vildagliptin mechanisms of action on islet function and glucose utilization. Research..
  43. ncbi request reprint Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake
    Jakob Ryskjaer
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, DK 2900 Hellerup, Denmark
    Eur J Endocrinol 155:485-93. 2006
    ..Therefore, the aim of the present study was to investigate plasma DPP-IV activity in the fasting and the postprandial state in type-2 diabetic patients and control subjects...
  44. ncbi request reprint Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo
    Astrid Plamboeck
    Department of Medical Physiology, Panum Institute, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Adv Exp Med Biol 524:303-12. 2003
  45. ncbi request reprint NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs
    Ulla Ribel
    Pharmacological Research 1, Health Care Pharmacology, Novo Nordisk A S, Novo Alle, DK 2880 Bagsvaerd, Denmark
    Eur J Pharmacol 451:217-25. 2002
    ..Therefore, NN2211, a GLP-1 derivative that can be administered once daily, holds promise as a new anti-diabetic drug with a minimal risk of hypoglycaemia...
  46. ncbi request reprint Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice
    P Thomas Gunnarsson
    Department of Medicine, Lund University, 22184 Lund, Sweden
    Endocrinology 147:3173-80. 2006
    ..We therefore conclude that fat and protein may serve as exogenous regulators of secretion and inactivation of the incretin hormones with beneficial influences on glucose metabolism...
  47. ncbi request reprint Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus
    Yan ling He
    Novartis Institutes for BioMedical Research, Inc, Cambridge, Massachusetts 02139 3584, USA
    Clin Pharmacokinet 46:577-88. 2007
    ..Vildagliptin is a dipeptidyl peptidase IV (DPP-4) inhibitor currently under development for the treatment of type 2 diabetes mellitus...
  48. pmc GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics
    Jeppe Sturis
    Discovery, Novo Nordisk A S, Novo Alle, DK 2880 Bagsvaerd, Denmark
    Br J Pharmacol 140:123-32. 2003
    ....
  49. ncbi request reprint Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs
    L Simonsen
    Department of Medical Physiology, Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Diabetologia 49:706-12. 2006
    ..Exendin-4 is less prone to enzymatic degradation, but it is still unclear what other factors contribute to the increased metabolic stability...
  50. ncbi request reprint Metabolism of glucagon-like peptide-2 in pigs: role of dipeptidyl peptidase IV
    Lene Hansen
    Department of Medical Physiology, University of Copenhagen, The Panum Institute, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Regul Pept 138:126-32. 2007
    ..However, DPP-IV is involved in the overall GLP-2 metabolism and seems to be the sole enzyme responsible for N-terminal degradation of GLP-2...
  51. doi request reprint Incretin and islet hormonal responses to fat and protein ingestion in healthy men
    Richard D Carr
    Novo Nordisk, Bagsvaerd, Denmark
    Am J Physiol Endocrinol Metab 295:E779-84. 2008
    ..We conclude that, whereas protein and fat release both incretin and islet hormones, the early GIP secretion after protein ingestion may be of primary importance to islet hormone secretion...
  52. ncbi request reprint Sensory nerve desensitization by resiniferatoxin improves glucose tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and is associated with reduced plasma activity of dipeptidyl peptidase IV
    Dorte X Gram
    Research and Development, Novo Nordisk A S, Måløv, Denmark
    Eur J Pharmacol 509:211-7. 2005
    ..Therefore, resiniferatoxin is a safe alternative to capsaicin for further investigations of the role of the sensory nerves in experimental diabetes...
  53. ncbi request reprint The reduction in hepatic insulin clearance after oral glucose is not mediated by gastric inhibitory polypeptide (GIP)
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Germany
    Regul Pept 113:95-100. 2003
    ..0001), but not the intravenous GIP administration (p=0.18) significantly reduced insulin clearance. Therefore, insulin clearance is reduced after an oral glucose load. This effect does not appear to be mediated by GIP...
  54. ncbi request reprint Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance
    Julio Rosenstock
    Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
    Diabetes Care 31:30-5. 2008
    ..This study was conducted to determine the effects of vildagliptin on incretin hormone levels, islet function, and postprandial glucose control in subjects with impaired glucose tolerance (IGT)...
  55. ncbi request reprint The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice
    Bidda Rolin
    Research and Development, Novo Nordisk A S, Måløv, Denmark
    Eur J Pharmacol 494:283-8. 2004
    ..This suggests that the GLP-1 metabolite is not involved in the regulation of glucose homeostasis...
  56. doi request reprint Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus
    Kristine J Hare
    Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    J Clin Endocrinol Metab 94:4679-87. 2009
    ..We investigated the dose-response relationship for GLP-1-induced glucagon suppression in patients with type 2 diabetes (T2DM) and healthy controls...
  57. pmc The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action
    Kristine J Hare
    Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
    Diabetes 59:1765-70. 2010
    ..The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes...
  58. doi request reprint Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes
    Meena Asmar
    Departments of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark
    Regul Pept 160:175-80. 2010
    ..Near-normoglycaemia reduced proinsulin/C-peptide ratio during stimulation with GLP-1, suggesting that strict glycaemic control might ameliorate some of the disturbances in beta-cell function characterizing T2DM...
  59. doi request reprint The incretin system and its role in type 2 diabetes mellitus
    Jens Juul Holst
    University of Copenhagen, Department of Biomedical Sciences, The Panum Institute, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Mol Cell Endocrinol 297:127-36. 2009
    ..Orally active DPP-4 inhibitors and the metabolically stable activators, exenatide (Byetta), are now on the market, and numerous clinical studies have shown that both principles are associated with durable antidiabetic activity...
  60. ncbi request reprint Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1
    Randi Ugleholdt
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, DK 2200 Copenhagen N, Denmark
    Endocrinology 145:1349-55. 2004
    ..These findings strongly suggest that PC1 is essential for intestinal proglucagon processing in vivo and, thereby, plays an important role in production of the incretin hormone GLP-1 and the intestinotrophic hormone GLP-2...
  61. ncbi request reprint Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus
    Jens Juul Holst
    Department of Medical Physiology, University of Copenhagen, The Panum Institute, DK 2200 Copenhagen N, Denmark
    Curr Opin Pharmacol 4:589-96. 2004
    ..Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials...
  62. ncbi request reprint Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs
    Ramona Trebbien
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Denmark
    Am J Physiol Endocrinol Metab 287:E431-8. 2004
    ..0 +/- 2.8 to 4.7 +/- 3.7%, M-RIA; 10.5 +/- 2.5 to 7.8 +/- 4.2%, N-RIA). This study provides evidence that NEP 24.11 is an important mediator of the degradation of both endogenous and exogenous glucagon in vivo...
  63. doi request reprint Glucagon-like peptide-1, glucose homeostasis and diabetes
    Jens J Holst
    Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, DK 2200 Copenhagen N, Denmark
    Trends Mol Med 14:161-8. 2008
    ..The pathophysiological basis the clinical use of these therapeutics is reviewed here...
  64. ncbi request reprint Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Bochum, Germany
    Diabetes 53:654-62. 2004
    ..Delayed elimination of GLP-1 and GIP in renal insufficiency may influence the pharmacokinetics and pharmacodynamics of dipeptidyl peptidase IV-resistant incretin derivatives to be used for the treatment of patients with type 2 diabetes...
  65. ncbi request reprint The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose
    Kristina M Utzschneider
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington and VA Puget Sound Health Care System, Seattle, Washington 98108, USA
    Diabetes Care 31:108-13. 2008
    ..To evaluate the effect of treatment with the dipeptidyl peptidase (DPP)-4 inhibitor vildagliptin on insulin sensitivity and beta-cell function in subjects with impaired fasting glucose (IFG)...
  66. ncbi request reprint The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects
    Tina Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, Denmark
    Regul Pept 137:168-72. 2006
    ..The primary metabolite, GIP 3-42, generated through the action of dipeptidyl peptidase IV (DPP-IV), was eliminated with a mean half-life of 17.5 and 20.5 min in patients and healthy subjects (NS)...
  67. ncbi request reprint Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Germany
    Metabolism 52:1579-85. 2003
    ..Therefore, a reduced GIP-induced insulin secretion in patients with type 2 diabetes and their first-degree relatives at hyperglycemia is more likely due to a general defect of B-cell function than to a specific defect of the GIP action...
  68. ncbi request reprint Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects
    Juris J Meier
    Department of Medicine, St Josef Hospiital, Ruhr University Bochum, Bochum, Germany
    Diabetes 53:S220-4. 2004
    ..Therefore, the existence of a specific GIP receptor defect in type 2 diabetes appears unlikely...
  69. ncbi request reprint Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University of Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    World J Gastroenterol 12:1874-80. 2006
    ..While animal experiments suggested a role for GIP as an inhibitor of gastric secretion, the GIP effects on gastric acid output in humans are still controversial...
  70. ncbi request reprint The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans
    Juris J Meier
    Dept of Medicine I, St Josef Hospital, Ruhr Univ Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Am J Physiol Endocrinol Metab 290:E1118-23. 2006
    ..Most likely, this is because of direct effects on glucose disposal. However, the glucose-lowering potential of GLP-1-(9-36) amide appears to be small compared with that of intact GLP-1-(7-36) amide...
  71. doi request reprint Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
    C F Deacon
    Department of Biomedical Sciences, University of Copenhagen, Panum Institute, Denmark
    Diabetes Obes Metab 13:7-18. 2011
    ..Long-term accumulated clinical experience will reveal whether compound-related characteristics lead to any clinically relevant differences...